Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

Depression Clinical Trial

Official title:

A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 and 200 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01072630
• Other study ID #: C10953/3072
• Secondary ID: 2009-016634-27
• Status: Completed
• Phase: Phase 3
• First received: February 19, 2010
• Last updated: April 26, 2016
• Start date: March 2010
• Est. completion date: November 2012

Study information

• Verified date: April 2016
• Source: Teva Pharmaceutical Industries
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The primary objective of the study is to determine whether armodafinil treatment, at a dosage of 150 mg/day, is more effective than placebo treatment as adjunctive therapy to mood stabilizers for treatment of adults with major depression associated with bipolar I disorder.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 492
• Est. completion date: November 2012
• Est. primary completion date: November 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• The patient has a diagnosis of bipolar I disorder according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria and is currently experiencing a major depressive episode.

• Documentation that the patient has had at least 1 previous manic or mixed episode.

• The patient has had no more than 6 mood episodes in the last year.

• The patient's current major depressive episode must have started no less than 2 weeks and no more than 12 months prior to the screening visit. The current depressive episode must have begun after the patient's current mood stabilizer regime began.

• The patient must have been taking 1 (or 2) of the following protocol-allowed mood stabilizers: lithium, valproic acid, lamotrigine, aripiprazole, olanzapine, risperidone, or ziprasidone (only if taken in combination with lithium or valproic acid).

• Written informed consent is obtained.

• The patient is a man or woman 18 through 65 years of age.

• The patient is in good health (except for diagnosis of bipolar I disorder) as judged by the investigator, on the basis of medical and psychiatric history, medical examination, electrocardiography (ECG), serum chemistry, hematology, and urinalysis.

• Women of childbearing potential (women who have not reached menopause, women who are less than 2 years postmenopausal, and women who are not surgically sterile) who are sexually active must use a medically accepted method of contraception and must agree to continue use of this method for the duration of the study and for 30 days after participation in the study.

• The patient is willing and able to comply with study restrictions and to attend regularly scheduled clinic visits as specified in this protocol.

• The patient has permanent accommodations and means of being contacted by the study center.

• The patient understands that they may enroll in this clinical study only once and may not enroll in any other clinical study while participating in this trial.

Exclusion Criteria:

• The patient has any Axis I disorder apart from bipolar I disorder that was the primary focus of treatment within 6 months of the screening visit or during the screening period.

• The patient has psychotic symptoms or has had psychosis within 4 weeks of the screening visit or during the screening period.

• The patient has current active suicidal ideation, is at imminent risk of self-harm, or has a history of significant suicidal ideation or suicide attempt at any time in the past that causes concern at present.

• The patient has a history of an eating disorder or obsessive compulsive disorder (OCD) within 6 months of the screening visit or during the screening period.

• The patient has a history of alcohol or substance abuse or dependence (with the exception of nicotine dependence) within 3 months of the screening visit or during the screening period.

• The patient has a history of any cutaneous drug reaction or drug hypersensitivity reaction, a history of any clinically significant hypersensitivity reaction, or a history of multiple clinically relevant allergies.

• The patient has any clinically significant uncontrolled medical condition, treated or untreated.

• The patient has received modafinil or armodafinil within the past 5 years, or the patient has a known sensitivity to any ingredients in the study drug tablets.

• The patient has previously participated in a clinical study with armodafinil or has used any investigational product within 90 days of screening. The patient may not enroll in any other clinical study while participating in this study.

• The patient has ever been treated with vagus nerve stimulation (VNS) or deep brain stimulation (DBS), or has been treated with electroconvulsive therapy (ECT) or repetitive transcranial magnetic stimulation (rTMS) within 3 months of the screening visit.

• The patient is a pregnant or lactating woman.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Depression
• Depressive Disorder
• Depressive Disorder, Major

Intervention

Drug:
• Armodafinil
Doses of either 150mg/day or 200 mg/day in tablet form taken orally, once daily in the morning.
• Placebo
Matching Placebo, also in tablet form taken orally, once daily in the morning.

Locations

Country	Name	City	State
Argentina	B.A. Psychiatric Research Cent	Buenos Aires
Argentina	Dr. Gregorio Hugo Sorin	Buenos Aires
Argentina	INECO	Buenos Aires
Argentina	Instituto FLENI	Buenos Aires
Argentina	Sanatorio Prof. León S. Morra SA	Córdoba
Argentina	Centro de Investigación y asistencia en Psiquiatria (CIAP)	Rosario
Australia	Neurotherapy Victoria Clinical Trials	Malvern	Victoria
Australia	Northern Area Mental Health Services Northern Psychiatric R	Melbourne	Victoria
Bulgaria	District Department of Psychiatric Disorders With Stationary	Bourgas
Bulgaria	State Psychiatric Hospital - Pazardjik	Pazardjik
Bulgaria	Psychiatric clinic for women UMHAT "Dr. Georgi Stranski"	Pleven
Bulgaria	ODPZS- EOOD, Plovdiv, Bulgaria	Plovdiv
Bulgaria	MHAT Doverie	Sofia
Bulgaria	Psychiatric clinic, University Hospital "Alexandrovska"	Sofia
Bulgaria	Diagnostic Consultative Center "Tchaika"	Varna
Bulgaria	MHAT - Sveta Marina	Varna
Canada	Grey Nuns Hospital	Edmonton	Alberta
Canada	Providence Care Mental Health Services	Kingston	Ontario
Canada	Medical Research Associates	Mississauga	Ontario
Canada	Hôpital Louis Hlafontaine	Montreal	Quebec
Canada	Dr. Alexander McIntyre, Inc.	Penticton	British Columbia
France	CMP/CHS du Jura	Dole
France	Centre Hospitalier de Jonzac	Jonzac
France	Hopital Universitaire Caremeau-Batiment Polyvalent, Service	Nîmes
Poland	Szpital Uniwersytecki im.dr.A.Jurasza w Bydgoszczy	Bydgoszcz
Poland	Klinika Chorob Psychicznych i Zaburzen Nerwicowych GUM	Gdansk
Poland	Wojewodzki Szpital Psychiatryczny im. prof. Tadeusza Bilikie	Gdansk
Poland	Malopolskie Centrum Medyczne	Krakow
South Africa	Cape Trial Centre	Cape Town
South Africa	Flexivest Fourteen Research Centre	Cape Town
South Africa	Knighton Surgery	Cape Town
South Africa	Vista Clinic	Centurion
South Africa	Dr Magnus & Dr Brink	Johannesburg
South Africa	Paarl Medical Centre	Paarl
South Africa	Dey Clinic	Pretoria
Spain	Hospital del Henares	Coslada (Madrid)
Spain	Clínica Universitaria de Navarra	Pamplona
Spain	Hospital Santiago Apostol	Vitoria
Spain	Hospital Psiquiátrico de Álava	Vitoria-Gasteiz
Ukraine	Donetsk National Medical University n.a. M. Horkyy	Donetsk
Ukraine	Public Institution "Institute of Neurology, Psychiatry and N	Kharkiv
Ukraine	Kiev City Psychoneurological Hospital N 1, CNTRP	Kiev
Ukraine	Danylo Galitsky Lviv State Medical University	Lviv
Ukraine	Odessa Regional Psychoneurology Dispensary	Odessa
Ukraine	Odessa Regional Mental Hospital #2	s. Oleksandrivka	Odessa
Ukraine	Vinnytsa National Medical University named by M.I. Pirogov	Vinnitsa
United States	Lehigh Center for Clinical Research	Allentown	Pennsylvania
United States	South Coast Medical Associates/SC Clinical Trials, Inc.	Anaheim	California
United States	Atlanta Center for Medical Research	Atlanta	Georgia
United States	FutureSearch Trials of Neurology	Austin	Texas
United States	Scientific Clinical Research, Inc.	Aventura	Florida
United States	North Coast Clinical Trials, Inc.	Beachwood	Ohio
United States	Birmingham Psychiatry Pharmaceutical Studies, Inc	Birmingham	Alabama
United States	Florida Clinical Research Center	Bradenton	Florida
United States	Behavioral Medical Research of Brooklyn	Brooklyn	New York
United States	Neuro-Behavioral Clinical Research, Inc	Canton	Ohio
United States	Comprehensive NeuroScience	Cerritos	California
United States	Community Research	Crestview Hills	Kentucky
United States	Insite Clinical Research	Desoto	Texas
United States	AccelRx Research	Fall River	Massachusetts
United States	Precise Research Centers	Flowood	Mississippi
United States	Hawaii Clinical Research Center	Honolulu	Hawaii
United States	Red Oak Psychiatry Associates, P.A.	Houston	Texas
United States	Sun Valley Behavioral Medical	Imperial	California
United States	University Hills Clinical Research	Irving	Texas
United States	Clinical Neuroscience Solutions Inc	Jacksonville	Florida
United States	Fidelity Clinical Research	Lauderhill	Florida
United States	CRI Worldwide, LLC	Mount Laurel	New Jersey
United States	Fieve Clinical Services, Inc.	New York	New York
United States	Medical and Behavioral Health Research	New York	New York
United States	Midwest Center for Neurobehavioral Medicine	Oakbrook Terrace	Illinois
United States	North County Clinical Research	Oceanside	California
United States	IPS Research Company	Oklahoma City	Oklahoma
United States	Aspen Clinical Research, LLC	Orem	Utah
United States	Compass Research, LLC	Orlando	Florida
United States	CNS - Comprehensive Neuro Science	Park Ridge	Illinois
United States	Belmont Center for Comprehensive Treatment	Philadelphia	Pennsylvania
United States	CNRI Los Angeles LLC	Pico Rivera	California
United States	Oregon Center for Clinical Investigators, Inc. (OCCI, Inc.)	Portland	Oregon
United States	Alliance Research Group	Richmond	Virginia
United States	Mayo College of Medicine	Rochester	Minnesota
United States	Clinical Methods	Salt Lake City	Utah
United States	CNRI-San Diego LLC	San Diego	California
United States	Clinical Innovations Inc.	Santa Ana	California
United States	Schuster Medical Research Institute	Sherman Oaks	California
United States	Carman Research	Smyrna	Georgia
United States	Stanford University Medical Center	Stanford	California
United States	Behavioral Medical Research of Staten Island	Staten Island	New York
United States	Richmond Behavioral Associates	Staten Island	New York
United States	Stedman Clinical Trials, LLC	Tampa	Florida
United States	Viking Clinical Research Center	Temecula	California
United States	Comprehensive NeuroScience	Washington DC	District of Columbia

Sponsors (1)

Lead Sponsor	Collaborator
Cephalon

Countries where clinical trial is conducted

United States,  Argentina,  Australia,  Bulgaria,  Canada,  France,  Poland,  South Africa,  Spain,  Ukraine, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline to Week 8 in the Total Score From the 30-Item Inventory of Depressive Symptomatology-Clinician-Rated (IDS-C30)	The IDS-C30 is a standardized 30-item, clinician-rated scale to assess the severity of a participant's depressive symptoms. Every effort was made to have the same rater evaluate a participant across all visits.; Total scores range from 0-84, with a score of 0 indicating no depression and a score of 84 indicating the most severe depression. Negative change from baseline values indicate improvement in the severity of depression.	Day 0 (baseline), Week 8	No
Secondary	Percentage of Responders At Different Treatment Weeks According to the 30-Item Inventory of Depressive Symptomatology-Clinician Rated (IDS-C30) Total Score	A responder is a participant with a =50% decrease or greater from baseline in the total score of the IDS-C30. The IDS-C30 is a standardized 30-item, clinician-rated scale to assess the severity of a participant's depressive symptoms. Every effort was made to have the same rater evaluate a participant across all visits.; Total scores range from 0-84, with a score of 0 indicating no depression and a score of 84 indicating the most severe depression.	Day 0 (baseline), Weeks 1, 2, 4, 6, 7, and 8, and last postbaseline observation (up to 8 weeks)	No
Secondary	Percentage of Participants in Remission At Different Treatment Weeks According to the 30-Item Inventory of Depressive Symptomatology-Clinician Rated (IDS-C30) Total Score	A participant in remission was defined as a participant with an IDS-C30 total score of 11 or less.; The IDS-C30 is a standardized 30-item, clinician-rated scale to assess the severity of a participant's depressive symptoms. Every effort was made to have the same rater evaluate a participant across all visits.; Total scores range from 0-84, with a score of 0 indicating no depression and a score of 84 indicating the most severe depression.	Weeks 1, 2, 4, 6, 7, and 8, and last postbaseline observation (up to 8 weeks)	No
Secondary	Change From Baseline to Different Treatment Weeks in the Total Score From the 30-Item Inventory of Depressive Symptomatology-Clinician-Rated (IDS-C30)	The IDS-C30 is a standardized 30-item, clinician-rated scale to assess the severity of a participant's depressive symptoms. Every effort was made to have the same rater evaluate a participant across all visits.; Total scores range from 0-84, with a score of 0 indicating no depression and a score of 84 indicating the most severe depression. Negative change from baseline values indicate improvement in the severity of depression.	Day 0 (baseline), Weeks 1, 2, 4, 6, 7, and 8, and last postbaseline observation (up to 8 weeks)	No
Secondary	Change From Baseline to Different Treatment Weeks in the Total Score From the 16-Item Quick Inventory of Depressive Symptomatology-Clinician-Rated (QIDS-C16)	The QIDS-C16 was derived from specified items in the IDS-C30, clinician-rated scale to assess the severity of a participant's depressive symptoms. Total scores range from 0-27, with a score of 0 indicating no depression and a score of 27 indicating the most severe depression. Negative change from baseline values indicate improvement in the severity of depression.	Day 0 (baseline), Weeks 1, 2, 4, 6, 7, and 8, and last postbaseline observation (up to 8 weeks)	No
Secondary	Change From Baseline to Different Treatment Weeks in the Clinical Global Impression of Severity (CGI-S) for Depression	The CGI-S is an observer-rated scale that measures illness severity on a 7-point scale, with the severity of illness scale using a range of responses from 1 (normal) through to 7 (amongst the most severely ill patients). Negative change from baseline values indicate improvement in the severity of depression.	Day 0 (baseline), Weeks 1, 2, 4, 6, 7, and 8, and last postbaseline observation (up to 8 weeks)	No
Secondary	Change From Baseline to Weeks 4, 8 and Endpoint in the Global Assessment for Functioning (GAF) Scale	The Global Assessment of Functioning (GAF) is a numeric scale (1 through 100) used by mental health clinicians and physicians to rate subjectively the social, occupational, and psychological functioning of adults, e.g., how well or adaptively one is meeting various problems-in-living. Ratings of 1 - 10 mean the participant is in persistent danger of severely hurting self or others (e.g., recurrent violence) or persistent inability to maintain minimal personal hygiene or serious suicidal act with clear expectation of death. Ratings of 91 - 100 indicate no symptoms, and the participant exhibits superior functioning in a wide range of activities, life's problems never seem to get out of hand, is sought out by others because of his or her many positive qualities. Positive change from baseline values indicate improvement in functioning.	Day 0 (baseline), Weeks 1, 2, 4, 6, 7, and 8, and last postbaseline observation (up to 8 weeks)	No
Secondary	Participants With Treatment-Emergent Adverse Events (TEAE)	AEs were graded by the investigator for severity on a three-point scale: mild, moderate and severe. Causality is graded as either related or not related. A serious adverse event (SAE) is an AE resulting in death, a life-threatening adverse event, hospitalization, a persistent or significant disability/incapacity, a congenital anomaly/birth defect, or an important medical event that may require medical intervention to prevent any of the previous results.; Protocol-defined adverse events requiring expedited reporting included skin rash, hypersensitivity reaction, emergent suicidal ideation or suicide attempt, and psychosis.	Day 1 to Week 9	Yes
Secondary	Change From Baseline to Endpoint in the Young Mania Rating Scale Total Score	The YMRS is a clinician-rated, 11-item checklist used to measure the severity of manic episodes. Information for assigning scores is gained from the participant's subjective reported symptoms over the previous 48 hours and from clinical observation during the interview. Seven items are ranked 0 through 4 and have descriptors associated with each severity level. Four items (irritability, speech, content, and disruptive-aggressive behavior) are scored 0 through 8 and have descriptors for every second increment. The total scale is 0-60. A score of =12 indicates remission of manic symptoms, and higher scores indicate greater severity of mania. Negative change from baseline scores indicate a decrease in severity of mania.	Day 0 (baseline), Week 8 or last postbaseline observation (up to 8 weeks)	Yes
Secondary	Change From Baseline to Endpoint in the Hamilton Anxiety Scale (HAM-A) Total Score	HAM-A measures the severity of anxiety symptoms. The scale consists of 14 items, each defined by a series of symptoms, and measures both psychic anxiety (mental agitation and psychological distress) and somatic anxiety (physical complaints related to anxiety). Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Negative change from baseline scores indicate a decrease in severity of anxiety.	Day 0 (baseline), Week 8 or last postbaseline observation (up to 8 weeks)	Yes
Secondary	Change From Baseline to Endpoint in the Insomnia Severity Index (ISI) Total Score	The ISI is a participant-rated, 7-item questionnaire designed to assess the severity of the participant's insomnia. Each item is ranked 0 (none) through 4 (very severe) and has a descriptor associated with each severity level. Total range is 0 (no insomnia) to 28 (very severe insomnia). Responses to each item are added to obtain a total score to determine the severity of insomnia. Negative change from baseline scores indicate a decrease in severity of insomnia.	Day 0 (baseline), Week 8 or last postbaseline observation (up to 8 weeks)	Yes
Secondary	Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Behavior - Actual Attempt Question	The C-SSRS is a clinician-rated scale that assesses suicidality from ideation to behaviors and monitors the potential emergence of suicidality in clinical studies. The C-SSRS-B (baseline) was performed at screening and the C-SSRS-SLV ('Since Last Visit') was performed at baseline and weeks 1, 2, 4, 6, 7, and 8 or last postbaseline observation. The Suicidal Behavior - Actual Attempt question records whether the participant committed a potentially self-injurious act with at least some wish to die since the last visit.	Weeks 1, 2, 4, 6, 7, 8, and Endpoint (up to 8 weeks)	Yes
Secondary	Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Behavior - Non-Suicidal Self-Injurious Behavior Question	The C-SSRS is a clinician-rated scale that assesses suicidality from ideation to behaviors and monitors the potential emergence of suicidality in clinical studies. The C-SSRS-B (baseline) was performed at screening and the C-SSRS-SLV ('Since Last Visit') was performed at baseline and weeks 1, 2, 4, 6, 7, and 8 or last postbaseline observation.; The Suicidal Behavior - Non-Suicidal Self-Injurious Behavior question records whether the participant committed a potentially self-injurious act that was not associated with a wish to die since the last visit.	Weeks 1, 2, 4, 6, 7, 8, and Endpoint (up to 8 weeks)	Yes
Secondary	Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Behavior - Interrupted Attempt Question	The C-SSRS is a clinician-rated scale that assesses suicidality from ideation to behaviors and monitors the potential emergence of suicidality in clinical studies. The C-SSRS-B (baseline) was performed at screening and the C-SSRS-SLV ('Since Last Visit') was performed at baseline and weeks 1, 2, 4, 6, 7, and 8 or last postbaseline observation.; The Suicidal Behavior - Interrupted Attempt question records whether the participant was interrupted by an outside circumstance from starting the potentially self-injurious act with at least some wish to die since the last visit.	Weeks 1, 2, 4, 6, 7, 8, and Endpoint (up to 8 weeks)	Yes
Secondary	Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Behavior - Aborted Attempt Question	The C-SSRS is a clinician-rated scale that assesses suicidality from ideation to behaviors and monitors the potential emergence of suicidality in clinical studies. The C-SSRS-B (baseline) was performed at screening and the C-SSRS-SLV ('Since Last Visit') was performed at baseline and weeks 1, 2, 4, 6, 7, and 8 or last postbaseline observation.; The Suicidal Behavior - Aborted Attempt question records whether the participant began to take steps toward making a suicide attempt but stops themselves before starting the potentially self-injurious act since the last visit.	Weeks 1, 2, 4, 6, 7, 8, and Endpoint (up to 8 weeks)	Yes
Secondary	Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Behavior - Suicidal Behavior Question	The C-SSRS is a clinician-rated scale that assesses suicidality from ideation to behaviors and monitors the potential emergence of suicidality in clinical studies. The C-SSRS-B (baseline) was performed at screening and the C-SSRS-SLV ('Since Last Visit') was performed at baseline and weeks 1, 2, 4, 6, 7, and 8 or last postbaseline observation.; The Suicidal Behavior - Suicidal Behavior question records whether in the clinician's opinion, the participant exhibited suicidal behavior since the last visit.	Weeks 1, 2, 4, 6, 7, 8, and Endpoint (up to 8 weeks)	Yes
Secondary	Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Behavior - Preparatory Acts or Behavior Question	The C-SSRS is a clinician-rated scale that assesses suicidality from ideation to behaviors and monitors the potential emergence of suicidality in clinical studies. The C-SSRS-B (baseline) was performed at screening and the C-SSRS-SLV ('Since Last Visit') was performed at baseline and weeks 1, 2, 4, 6, 7, and 8 or last postbaseline observation.; The Suicidal Behavior - Preparatory Acts or Behavior question records whether the participant exhibited acts or preparations towards imminently making a suicide attempt since the last visit.	Weeks 1, 2, 4, 6, 7, 8, and Endpoint (up to 8 weeks)	Yes
Secondary	Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Behavior - Completed Suicide Question	The C-SSRS is a clinician-rated scale that assesses suicidality from ideation to behaviors and monitors the potential emergence of suicidality in clinical studies. The C-SSRS-B (baseline) was performed at screening and the C-SSRS-SLV ('Since Last Visit') was performed at baseline and weeks 1, 2, 4, 6, 7, and 8 or last postbaseline observation.; The Suicidal Behavior - Completed Suicide question records whether the participant intentionally causing his/her's own death since the last visit.	Weeks 1, 2, 4, 6, 7, 8, and Endpoint (up to 8 weeks)	Yes
Secondary	Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Ideation - Wish to Be Dead Question	The C-SSRS is a clinician-rated scale that assesses suicidality from ideation to behaviors and monitors the potential emergence of suicidality in clinical studies. The C-SSRS-B (baseline) was performed at screening and the C-SSRS-SLV ('Since Last Visit') was performed at baseline and weeks 1, 2, 4, 6, 7, and 8 or last postbaseline observation.; The Suicidal Ideation - Wish to Be Dead question records whether the participant endorses thoughts about a wish to dead or not alive anymore, or a wish to fall asleep and not wake up since the last visit.	Weeks 1, 2, 4, 6, 7, 8, and Endpoint (up to 8 weeks)	Yes
Secondary	Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Ideation - Non-Specific Active Suicidal Thoughts Question	The C-SSRS is a clinician-rated scale that assesses suicidality from ideation to behaviors and monitors the potential emergence of suicidality in clinical studies. The C-SSRS-B (baseline) was performed at screening and the C-SSRS-SLV ('Since Last Visit') was performed at baseline and weeks 1, 2, 4, 6, 7, and 8 or last postbaseline observation.; The Suicidal Ideation - Non-Specific Active Suicidal Thoughts question records whether the participant shares general non-specific thoughts of wanting to end one's life/commit suicide since the last visit.	Weeks 1, 2, 4, 6, 7, 8, and Endpoint (up to 8 weeks)	Yes
Secondary	Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Ideation - Any Methods (Not Plan) Without Intent to Act Question	The C-SSRS is a clinician-rated scale that assesses suicidality from ideation to behaviors and monitors the potential emergence of suicidality in clinical studies. The C-SSRS-B (baseline) was performed at screening and the C-SSRS-SLV ('Since Last Visit') was performed at baseline and weeks 1, 2, 4, 6, 7, and 8 or last postbaseline observation.; The Suicidal Ideation - Any Methods (Not Plan) Without Intent to Act question records whether the participant endorses thoughts of suicide and has thought of at least one method but has no specific plan of action since the last visit.	Weeks 1, 2, 4, 6, 7, 8, and Endpoint (up to 8 weeks)	Yes
Secondary	Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Ideation - Some Intent to Act Without a Specific Plan Question	The C-SSRS is a clinician-rated scale that assesses suicidality from ideation to behaviors and monitors the potential emergence of suicidality in clinical studies. The C-SSRS-B (baseline) was performed at screening and the C-SSRS-SLV ('Since Last Visit') was performed at baseline and weeks 1, 2, 4, 6, 7, and 8 or last postbaseline observation.; The Suicidal Ideation - Some Intent to Act Without a Specific Plan question records whether the participant has active suicidal thoughts of killing oneself and reports having some intent to act on such thoughts since the last visit.	Weeks 1, 2, 4, 6, 7, 8, and Endpoint (up to 8 weeks)	Yes
Secondary	Columbia-Suicide Severity Rating Scale 'Since Last Visit' Version (C-SSRS-SLV) For Weeks 1, 2, 4, 6, 7, 8, and Endpoint For the Suicidal Ideation - Specific Plan and Intent Question	The C-SSRS is a clinician-rated scale that assesses suicidality from ideation to behaviors and monitors the potential emergence of suicidality in clinical studies. The C-SSRS-B (baseline) was performed at screening and the C-SSRS-SLV ('Since Last Visit') was performed at baseline and weeks 1, 2, 4, 6, 7, and 8 or last postbaseline observation.; The Suicidal Ideation - Specific Plan and Intent question records whether the participant has active suicidal thoughts of killing oneself with details of plan fully or partially worked out and the participant has some intent to carry out the plan since the last visit.	Weeks 1, 2, 4, 6, 7, 8, and Endpoint (up to 8 weeks)	Yes